No Detail Found!

Guillain-barré syndrome: recent approaches in pathophysiology, diagnosis and management

Author(s)
Fatima Zahir Liaquat National Hospital and Medical College (LNMC), National Stadium Road, Karachi 74800, Pakistan.
Ghulam Zainab Liaquat National Hospital and Medical College (LNMC), National Stadium Road, Karachi 74800, Pakistan.
Malaika Ata Karim Liaquat National Hospital and Medical College (LNMC), National Stadium Road, Karachi 74800, Pakistan.
Abstract
Guillain-Barré syndrome (GBS) was named after the French neurologists Georges Guillain and Jean Alexandre Barré who together with a French physician André Strohl in 1916 described this condition. In view of the controversies in understanding the GBS and its subtypes, we have attempted in the present review to present the general background literature related to GBS, its causes, pathophysiology, diagnosis, treatment and other management measures, prognosis and future directions for better health care of the patients with various forms of GBS. Treatment of GBS is a challenge for the patients and physicians, since it has various levels of severity in different areas of the body and in different cases. There is an urgent need of establishing the molecular understanding of the potential biological treatments. Besides immunotherapy, there seems strong evidence of biological substances that can help modulating the pathogenesis processes of GBS. We suggest that the promising studies for biological targets and biological and clinicobiological basis of innovative immunotherapeutic approaches for investigating/ inventing the biological drugs are essentially required for the treatment and better outcome of GBS complications.
Publication Details
Page(s) 299-306
DOI DOI not available
Published Journal: International Journal of Biology and Biotechnology, Volume: 21, Issue: 3, Year: 2024

Request the full text from PASTIC

Keywords
Diagnosis, management and prognosis, future recommendations, Guillain-Barré syndrome (GBS), causes and pathophysiology, GBS variants
References
Abu-Rumeileh S.,Abdelhak A.,Foschi M.,Tumani H.,Otto M. .2021 .Guillain-Barré syndrome spectrum associated with COVID-19: an up-to-date systematic review of 73 cases. , 268(4) : 1133-1170.
Brown T.E.,Feasby T.E. .1984 .Conduction block and denervation in Guillain-Barré polyneuropathy. Brain, 107 : 219-39.
Dantal J. .2013 .Intravenous immunoglobulins: in-depth review of excipients and acute kidney injury risk. Am J Nephrol., 38(4) : 275-84.
Darweesh S.K.,Polinder S.,M.J. Mulder S,Baena C.P.,Leeuwen O.H.,Franco B.C.,Jacobs P.A. van Doorn .2014 .Health-related quality of life in Guillain-Barré syndrome patients: a systematic review. J Peripher Nerv Syst., 19(1) : 24-35.
Davidson A.I.,Halstead S.K.,Goodfellow J.A.,Chavada G.,Mallik A.,Overell J.,Lunn M.P.,McConnachie A.,Willison P. van Doorn and H. J. .2017 .Inhibition of complement in Guillain-Barré syndrome: the ICA-GBS study. J Peripher Nerv Syst., 22(1) : 4-12.
DeStefano H.M.,Bodenstab P.A.,Offit P.A. .2019 .Principal Controversies in Vaccine Safety in the United States. Clin Infect Dis, 69(4) : 726-731.
Dimachkie M.,Barohn M. .2013 .Guillain-Barré syndrome and variants. Neurol Clin., 31(2) : 491-510.
Eldar A.H.,Chapman J A.H. .2014 .Guillain Barré syndrome and other immune mediated neuropathies: diagnosis and classification. Autoimmun Rev., 13(4-5) : 525-30.
Ellul M.A.,Benjamin L.,Singh B.,Lant S.,Michael B.D.,Easton A.,Kneen R.,Defres S.,Sejvar J.,Solomon T. .2020 .Neurological associations of COVID-19. , 19(9) : 767-783.
Finsterer J.,Scorza F.A.,Scorza C.A.,Fiorini A. C. .2021 .Peripheral neuropathy in COVID-19 is due to immune-mechanisms, pre-existing risk factors, anti-viral drugs, or bedding in the Intensive Care Unit. , 79(10) : 924-928.
Garg M. .2017 .Respiratory Involvement in Guillain-Barre Syndrome: The Uncharted Road to Recovery. J Neurosci Rural Pract, 8(3) : 325-326.
Gatherer D.,Kohl A .2016 .Zika virus: a previously slow pandemic spreads rapidly through the Americas. , 97(2) : 269-273.
Guillan G.,Barré J. A.,Strohl A .1916 .Sur un syndrome de radiculo-névrite avec hyperalbuminose du liquid cephalorachidien sans réaction cellulaire. Remarques sur les caracteres cliniques et graphiques des reflexes tendineux. Bull Soc Méd, 40 : 1462-70.
Hagen S.S.,Ousman S.S. .2020 .The Neuroimmunology of Guillain-Barré Syndrome and the Potential Role of an Aging Immune System. Front Aging Neurosci. , 613628 : 613628.
Hegen H.,Ladstätter F.,Auer M.,Berek K.,Di Pauli F.,Walde J.,Wanschitz J.,Zinganell A.,Deisenhammer F. .2021 .Cerebrospinal fluid protein in Guillain-Barré syndrome: Need for age-dependent interpretation. Eur J Neurol., 28(3) : 965-973.
Harms M. .2011 .Inpatient management of guillain-barré syndrome. Neurohospitalist, 10(2) : PMC3726082-84.
Hughes R.A.,Wijdicks E.F.,Barohn R.,Benson E.,Cornblath D.R.,Hahn A.F.,Meythaler J.M.,Miller R.G.,Sladky J.T.,J.C. J.T. .2003 .Practice parameter: immunotherapy for Guillain-Barré syndrome: report of the Quality Standards Subcommittee of the American Academy of Neurology. , 61(6) : 736-40.
Hughes R.A.,Swan A.V.,Raphaël J.C.,Annane D.,R. van Koningsveld and van Doorn PA D. .2007 .Immunotherapy for Guillain-Barré syndrome: a systematic review. Brain, 130 : 2245-57.
Hughes R.A.,Brassington R.,Gunn A.A.,P.A. van Doorn A.A. .2016 .Corticosteroids for Guillain-Barré syndrome. PMID: 27775812; PMCID: PMC6464149., 10(10) : .
Islam Z.,Papri N.,Ishaque T.,Alam A.U.,Islam I. Jahan B.,Mohammad Q.D. .2019 .Risk factors for respiratory failure in Guillain-Barré syndrome in Bangladesh: a prospective study. Ann Clin Transl Neurol, 6(2) : 324-332.
Khan F.,Amatya B. .2012 .Rehabilitation interventions in patients with acute demyelinating inflammatory polyneuropathy: a systematic review. Eur J Phys Rehabil Med, 48(3) : 507-22.
Korinthenberg R.,Eckenweiler M.,Fuchs M. .2021 .Severe Locked-In-Like Guillain-Barré's Syndrome: Dilemmas in Diagnosis and Treatment. , 52(1) : 19-26.
Kuwabara S. and N.,Yuki S. and N. .2013 .Axonal Guillain-Barré syndrome: concepts and controversies. Lancet Neurol, 12(12) : 1180-8.
Liu J.,Wang L.N.,McNicol E.D. .2015 .4):CD009950. PMID: 25855461; PMCID: PMC6361619., 10 : .
Liu S.,Dong C.,Ubogu E.E. .2018 .Immunotherapy of Guillain-Barré syndrome. Hum Vaccin Immunother., 14(11) : 2568-2579.
Liu H.,Lv H.G.,Zhang R. .2023 .Variant of Guillain-Barré syndrome with anti-sulfatide antibody positivity and spinal cord involvement: A case report. World J Clin Cases, 11(26) : 6274-6279.
Liu S.,Zhang W.W.,Zhang H.L. .2024 .Guillain-Barré syndrome: immunopathogenesis and therapeutic targets. Expert Opin Ther Targets, 18 : 1-13.
Matarneh A.S.,Al-Battah A.H.,Farooqui K.,Ghamoodi M.,Alhatou M. .2021 .COVID-19 vaccine causing Guillain-Barre syndrome, a rare potential side effect. Clin Case Rep., 9, 10(9) : 4756.
Merchant H. .2022 .Inadvertent injection of COVID-19 vaccine into deltoid muscle vasculature may result in vaccine distribution to distance tissues and consequent adverse reactions. Postgrad Med, 10(1161) : 98.
Nelson K.E. .2012 .Invited commentary: Influenza vaccine and Guillain-Barre syndrome--is there a risk? Am J Epidemiol. , 175(11) : 1129-32.
Packiyarajah P.,Sundaresan and M.S.M. Nusair K.T. .2023 .. Rare Sensory Ataxic Variant of Guillain-Barre Syndrome: A Case Report., Cureus, 10(6) : .
Patone M.,Handunnetthi L.,Saatci D.,Pan J.,Katikireddi S.V.,Razvi S.,Hunt D.,Mei X.W.,Dixon S.,Zaccardi F.,Khunti K.,Watkinson P.,Coupland A.A.C.,Doidge J.,Harrison D.A.,Ravanan R.,Sheikh A.,Robertson C.,Hippisley-Cox J. .2021 .Neurological complications after first dose of COVID-19 vaccines and SARS-CoV-2 infection. Nat Med, 27(12) : 2144-2153.
Pimentel V.,Luchsinger V.W.,Carvalho G.L.,Alcará A.M.,Esper N.B.,Marinowic D.,Zanirati G.,Costa J.C. .2022 .Guillain-Barré syndrome associated with COVID-19: A systematic review. Brain Behav Immun Health, 100578 : 100578.
Rinaldi S. .2013 .Update on Guillain-Barré syndrome. J Peripher Nerv Syst., 18(2) : 99-112.
Ropper A.H. .1992 .The Guillain-Barré syndrome. N Engl J Med, 326(17) : 1130-6.
Ryan M.M. .2013 .Pediatric Guillain-Barré syndrome. Curr Opin Pediatr., 25(6) : 689-93.
Saeed M.L.,Baloch B Kaleem,Mahmud S.N.,Khan M.T.,Qureshi M.S.S.,Shad Z.S.,Hussain S.W.,Munawar K.,Qadeer A.,Abdullah A,Yuki N. .2013 .Bickerstaff brainstem encephalitis and Fisher syndrome: anti-GQ1b antibody syndrome. J Neurol Neurosurg Psychiatry, 22984203(5) : 576-83.
Shahrizaila N.,Lehmann H.C.,Kuwabara S. .2021 .Guillain-Barré syndrome. Lancet, 397(10280) : 1214-1228.
Spasovski G.,Vanholder R.,Allolio B.,Annane D.,Ball D. Bichet S.,D S.,Fenske W.,Hoorn E.J.,Ichai C.,Joannidis M.,Soupart A.,Zietse R.,Haller M.,E. Nagler; M. .2014 .Clinical practice guideline on diagnosis and treatment of hyponatraemia. Eur J Endocrinol., 170(3) : G1-47.
Toscano G.,Palmerini F.,Ravaglia S.,Ruiz L.,Invernizzi P.,Cuzzoni M.G.,Franciotta D.,Baldanti F.,Daturi R.,Postorino P.,Cavallini A.,Micieli G.,Engl J Med N .2020 .Guillain-Barré Syndrome Associated with SARS-CoV-2. , 382(26) : 2574-2576.
Uncini A,Kuwabara S. .2012 .Electrodiagnostic criteria for Guillain-Barrè syndrome: a critical revision and the need for an update. Clin Neurophysiol., 123(8) : 1487-95.
van den Berg ,C. Walgaard J.,Drenthen C.,Fokke J.B.,Jacobs P.A. van Doorn .2014 .Guillain-Barré syndrome: pathogenesis, diagnosis, treatment and prognosis. Nat Rev Neurol, 10(8) : 469-82.
Vellozzi C.,Iqbal S.,Broder K. .2014 .Guillain-Barre syndrome, influenza, and influenza vaccination: the epidemiologic evidence. Clin Infect Dis, 58(8) : 1149-55.
Perera V.N.,I. Nachamkin V.N.,Ung H.,Patterson J.H.,M.J. McConville P.J.,Coloe B.N.,Fry B.N. .2007 .Molecular mimicry in Campylobacter jejuni: role of the lipo-oligosaccharide core oligosaccharide in inducing antiganglioside antibodies. FEMS Immunology & Medical Microbiology, 50(1) : 27-36.
Wakerley B.R.,Uncini A.,N. A. .2014 .GuillainBarré and Miller Fisher syndromes--new diagnostic classification. Nat Rev Neurol, 10(9) : 537-44.
Walgaard C.,Jacobs B.C.,P.A. van Doorn B.C. .2011 .Emerging drugs for Guillain-Barré syndrome. Expert Opin Emerg Drugs, 16(1) : 105-20.
Wang Y.Z.,Lv H.,Shi Q.G.,Fan X.T.,Li L.,Yi Wong A.H.,Hao Y.L.,Si C.P.,Li C.L.,Yuki N. .2015 .Action mechanism of corticosteroids to aggravate Guillain-Barré syndrome. Sci Rep., 10 : 13931.
Willison C.S.,Goodyear C.S. .2013 .Glycolipid antigens and autoantibodies in autoimmune neuropathies. Trends Immunol, 34(9) : 453-9.
Ye Y.,Zhu D.,Wang K.,J. Wu J.,Feng D.,Ma Y.,Xing X.,Jiang X. .2010 .Clinical and electrophysiological features of the 2007 Guillain-Barré syndrome epidemic in northeast China. Muscle Nerve, 42(3) : 311-4.
Yikilmaz A,Doganay S.,Gumus H.,Per H.,Kumandas S.,Coskun A .2010 .Magnetic resonance imaging of childhood Guillain-Barre syndrome. Childs Nerv Syst., 26(8) : 1103-8.
Yoshikawa K.,Kuwahara M.,Morikawa M.,Kusunoki S. .2020 .Bickerstaff brainstem encephalitis with or without anti-GQ1b antibody. , 10(6) : .
Yuki N. and H.P.,Hartung N. and H.P. .2012 .Guillain-Barré syndrome. N Engl J Med, 366(24) : 2294-304.
Zhang L.,Ma L.,Zhou L.,Sun Q,Fang Q .2023 .Miller-Fisher syndrome with positive anti-GD1b and anti-GM1 antibodies combined with multiple autoimmune antibodies: A case report. Medicine (Baltimore), 10(34) : .
0

Citations

0

Downloads

63

Views